Inogen, Inc (NASDAQ:INGN - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Friday following a dissappointing earnings announcement. The stock has a 200-day moving average of $6.23 and traded as low as $5.05. Inogen shares last traded at $6.03, with a volume of 974,912 shares.
The medical technology company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.42). The firm had revenue of $77.19 million during the quarter, compared to analysts' expectations of $92.25 million. Inogen had a negative return on equity of 13.17% and a negative net margin of 6.94%.
Inogen News Summary
Here are the key news stories impacting Inogen this week:
- Positive Sentiment: Inogen appointed Andy Reding as president and CEO and launched a $20 million cost-reduction program aimed at accelerating profitability. The savings could help improve results, though execution will be important. Inogen Announces Third Quarter 2026 Financial Results
- Neutral Sentiment: The company completed the sale of its U.S. oxygen rental business to Rotech on November 2. The divestiture changes the business mix, but the provided reports do not specify the sale’s financial impact. Leadership Transition and Cost-Reduction Program
- Neutral Sentiment: Trading in INGN was temporarily paused under a Limit Up-Limit Down (LULD) halt. The halt itself does not indicate the direction of the stock move.
- Negative Sentiment: Third-quarter revenue was $77.19 million versus analysts’ $92.25 million estimate, while loss per share was $0.56 versus an expected $0.14 loss—substantial misses that may weigh on investor confidence. Third-Quarter 2026 Financial Results
- Negative Sentiment: Inogen forecast FY 2026 revenue of $298 million–$301 million, far below the $356.4 million consensus. Its Q4 revenue outlook of $65 million–$68 million also trails the $84 million estimate, signaling a weaker near-term revenue outlook. Third-Quarter 2026 Financial Results
Wall Street Analyst Weigh In
Separately, Weiss Ratings restated a "sell (d-)" rating on shares of Inogen in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Inogen has a consensus rating of "Moderate Buy".
View Our Latest Analysis on Inogen
Institutional Investors Weigh In On Inogen
Several hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. purchased a new position in Inogen during the second quarter valued at $11,281,000. Arrowstreet Capital Limited Partnership lifted its position in Inogen by 203.9% during the first quarter. Arrowstreet Capital Limited Partnership now owns 586,159 shares of the medical technology company's stock valued at $3,622,000 after purchasing an additional 393,310 shares in the last quarter. Moore Capital Management LP raised its stake in Inogen by 3.3% during the 2nd quarter. Moore Capital Management LP now owns 289,128 shares of the medical technology company's stock worth $1,865,000 after acquiring an additional 9,229 shares during the period. Readystate Asset Management LP purchased a new stake in Inogen in the 2nd quarter worth $1,718,000. Finally, Monaco Asset Management SAM purchased a new stake in Inogen during the 2nd quarter valued at approximately $1,037,000. 89.94% of the stock is owned by institutional investors and hedge funds.
Inogen Stock Performance
The business's fifty day simple moving average is $5.96 and its 200-day simple moving average is $6.23. The company has a market capitalization of $160.04 million, a P/E ratio of -4.60 and a beta of 1.51.
About Inogen
(
Get Free Report)
Inogen, Inc is a medical technology company that develops, manufactures and markets portable oxygen concentrators for people who require long-term supplemental oxygen therapy. Its devices separate oxygen from ambient air and deliver concentrated oxygen without the need for traditional compressed-gas or liquid-oxygen tanks.
The company's product portfolio has included the Inogen One portable oxygen concentrator line, as well as stationary and related oxygen therapy products. These systems are designed to support mobility and independence for patients with chronic respiratory conditions while offering features such as rechargeable batteries, portability and various oxygen-delivery settings.
Founded in 2001 and headquartered in Goleta, California, Inogen sells its products through direct-to-consumer channels, health-care providers, distributors and other commercial partners.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Inogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inogen wasn't on the list.
While Inogen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
